Literature DB >> 8497060

Juxtaposition between activation and basic domains of human immunodeficiency virus type 1 Tat is required for optimal interactions between Tat and TAR.

Y Luo1, B M Peterlin.   

Abstract

trans activation of the human immunodeficiency virus type 1 long terminal repeat requires that the viral trans activator Tat interact with the trans-acting responsive region (TAR) RNA. Although the N-terminal 47 amino acids represent an independent activation domain that functions via heterologous nucleic acid-binding proteins, sequences of Tat that are required for interactions between Tat and TAR in cells have not been defined. Although in vitro binding studies suggested that the nine basic amino acids from positions 48 to 57 in Tat bind efficiently to the 5' bulge in the TAR RNA stem-loop, by creating several mutants of Tat and new hybrid proteins between Tat and the coat protein of bacteriophage R17, we determined that this arginine-rich domain is not sufficient for interactions between Tat and TAR in vivo. Rather, the activation domain is also required and must be juxtaposed to the basic domain. Thus, in vitro TAR RNA binding does not translate to function in vivo, which suggests that other proteins are important for specific and productive interactions between Tat and TAR.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8497060      PMCID: PMC237689          DOI: 10.1128/JVI.67.6.3441-3445.1993

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  26 in total

Review 1.  New insights into the mechanism of HIV-1 trans-activation.

Authors:  J Karn; M A Graeble
Journal:  Trends Genet       Date:  1992-11       Impact factor: 11.639

2.  Two distinct nuclear transcription factors recognize loop and bulge residues of the HIV-1 TAR RNA hairpin.

Authors:  C T Sheline; L H Milocco; K A Jones
Journal:  Genes Dev       Date:  1991-12       Impact factor: 11.361

3.  The nut site of bacteriophage lambda is made of RNA and is bound by transcription antitermination factors on the surface of RNA polymerase.

Authors:  J R Nodwell; J Greenblatt
Journal:  Genes Dev       Date:  1991-11       Impact factor: 11.361

4.  Detailed mutational analysis of TAR RNA: critical spacing between the bulge and loop recognition domains.

Authors:  B Berkhout; K T Jeang
Journal:  Nucleic Acids Res       Date:  1991-11-25       Impact factor: 16.971

5.  Mutational analysis of the conserved basic domain of human immunodeficiency virus tat protein.

Authors:  J Hauber; M H Malim; B R Cullen
Journal:  J Virol       Date:  1989-03       Impact factor: 5.103

6.  HIV-1 tat trans-activation requires the loop sequence within tar.

Authors:  S Feng; E C Holland
Journal:  Nature       Date:  1988-07-14       Impact factor: 49.962

7.  Specific binding of arginine to TAR RNA.

Authors:  J Tao; A D Frankel
Journal:  Proc Natl Acad Sci U S A       Date:  1992-04-01       Impact factor: 11.205

8.  A minimal lentivirus Tat.

Authors:  D Derse; M Carvalho; R Carroll; B M Peterlin
Journal:  J Virol       Date:  1991-12       Impact factor: 5.103

9.  Assembly of transcription elongation complexes containing the N protein of phage lambda and the Escherichia coli elongation factors NusA, NusB, NusG, and S10.

Authors:  S W Mason; J Greenblatt
Journal:  Genes Dev       Date:  1991-08       Impact factor: 11.361

10.  Human immunodeficiency virus type 1 LTR TATA and TAR region sequences required for transcriptional regulation.

Authors:  J A Garcia; D Harrich; E Soultanakis; F Wu; R Mitsuyasu; R B Gaynor
Journal:  EMBO J       Date:  1989-03       Impact factor: 11.598

View more
  10 in total

1.  Structural mechanism for HIV-1 TAR loop recognition by Tat and the super elongation complex.

Authors:  Ursula Schulze-Gahmen; James H Hurley
Journal:  Proc Natl Acad Sci U S A       Date:  2018-12-04       Impact factor: 11.205

2.  Selection of TAR RNA-binding chameleon peptides by using a retroviral replication system.

Authors:  Baode Xie; Valerie Calabro; Mark A Wainberg; Alan D Frankel
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

3.  Identification of specific molecular structures of human immunodeficiency virus type 1 Tat relevant for its biological effects on vascular endothelial cells.

Authors:  S Mitola; R Soldi; I Zanon; L Barra; M I Gutierrez; B Berkhout; M Giacca; F Bussolino
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

4.  The 5' UTR of HIV-1 full-length mRNA and the Tat viral protein modulate the programmed -1 ribosomal frameshift that generates HIV-1 enzymes.

Authors:  Johanie Charbonneau; Karine Gendron; Gerardo Ferbeyre; Léa Brakier-Gingras
Journal:  RNA       Date:  2012-01-27       Impact factor: 4.942

5.  Inhibition of human immunodeficiency virus type 1 and type 2 Tat function by transdominant Tat protein localized to both the nucleus and cytoplasm.

Authors:  M J Orsini; C M Debouck
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

6.  Cell cycle-regulated transcription by the human immunodeficiency virus type 1 Tat transactivator.

Authors:  F Kashanchi; E T Agbottah; C A Pise-Masison; R Mahieux; J Duvall; A Kumar; J N Brady
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

7.  Effects of human chromosome 12 on interactions between Tat and TAR of human immunodeficiency virus type 1.

Authors:  A Alonso; T P Cujec; B M Peterlin
Journal:  J Virol       Date:  1994-10       Impact factor: 5.103

8.  The leucine domain of the visna virus Tat protein mediates targeting to an AP-1 site in the viral long terminal repeat.

Authors:  L M Carruth; B A Morse; J E Clements
Journal:  J Virol       Date:  1996-07       Impact factor: 5.103

9.  Visna virus Tat protein: a potent transcription factor with both activator and suppressor domains.

Authors:  L M Carruth; J M Hardwick; B A Morse; J E Clements
Journal:  J Virol       Date:  1994-10       Impact factor: 5.103

10.  Naturally occurring genotypes of the human immunodeficiency virus type 1 long terminal repeat display a wide range of basal and Tat-induced transcriptional activities.

Authors:  N L Michael; L D'Arcy; P K Ehrenberg; R R Redfield
Journal:  J Virol       Date:  1994-05       Impact factor: 5.103

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.